Targeting Inflammatory Pathways by Triterpenoids for Prevention and Treatment of Cancer by Yadav, Vivek R. et al.
Toxins 2010, 2, 2428-2466; doi:10.3390/toxins2102428 
 
toxins 
ISSN 2072-6651 
www.mdpi.com/journal/toxins 
Review 
Targeting Inflammatory Pathways by Triterpenoids 
for Prevention and Treatment of Cancer 
Vivek R. Yadav, Sahdeo Prasad, Bokyung Sung, Ramaswamy Kannappan and  
Bharat B. Aggarwal * 
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas 
M.D. Anderson Cancer Center, Houston 77030, TX, USA; E-Mail: vryadav@mdanderson.org (V.R.Y.) 
*  Author to whom correspondence should be addressed; E-Mail: aggarwal@mdanderson.org;  
Tel.: +1 713 794 1817; Fax: +1 713 606 3399. 
Received: 30 August 2010; in revised form: 23 September 2010 / Accepted: 15 October 2010 /  
Published: 22 October 2010  
 
Abstract:  Traditional medicine and diet has served mankind through the ages for 
prevention and treatment of most chronic diseases. Mounting evidence suggests that 
chronic inflammation mediates most chronic diseases, including cancer. More than other 
transcription factors, nuclear factor-kappaB (NF-κB) and STAT3 have emerged as major 
regulators of inflammation, cellular transformation, and tumor cell survival, proliferation, 
invasion, angiogenesis, and metastasis. Thus, agents that can inhibit NF-κB and STAT3 
activation pathways have the potential to both prevent and treat cancer. In this review, we 
examine the potential of one group of compounds called triterpenes, derived from 
traditional medicine and diet for their ability to suppress inflammatory pathways linked to 
tumorigenesis. These triterpenes include avicins, betulinic acid, boswellic acid, celastrol, 
diosgenin, madecassic acid, maslinic acid, momordin, saikosaponins, platycodon, 
pristimerin, ursolic acid, and withanolide. This review thus supports the famous adage of 
Hippocrates, “Let food be thy medicine and medicine be thy food”.  
Keywords:  triterpenoids; nuclear factor-κB; inflammation; tumor cell proliferation; 
invasion; angiogenesis; apoptosis 
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1. Introduction 
Natural compounds have been used extensively in the treatment of many diseases and are of interest 
to researchers both in their natural forms and as templates for synthetic modification. Natural 
compounds currently used in medicine exhibit a very wide chemical diversity, and together with their 
analogues and several other natural products, they demonstrate the importance of compounds from 
natural sources in modern drug discovery efforts. Sample sources and molecular mechanisms are 
highly important in the development of novel, clinically useful anticancer agents [1]. Interest in natural 
compounds has grown in recent years because of concerns about drug costs and safety. For example, 
glioblastoma kills almost everyone who gets it, usually in a little over a year. In effect, the $1.3 billion 
spent by a pharmaceutical company on a new glioblastoma drug discovery had the limited impact of 
improving patients’ lives for about one year. This illustrates the need for new sources for drug 
discovery, and natural sources provide valuable information for research in this area. During the past 
decade, tremendous progress has been made toward understanding the cellular and molecular 
mechanisms underlying the process of carcinogenesis, leading to the development of potential cancer 
prevention options termed chemoprevention [2]. The goal of chemoprevention is to use noncytotoxic 
natural agents to inhibit or reverse the development and progression of precancerous cells [3]. 
Cancer is a complicated disease that may develop in humans over a number of years (Figure 1). 
Development of a tumor starts with a normal cell that is transformed through the activation of 
proto-oncogenes and the suppression of tumor suppressor genes such as p53. The transformed cell no 
longer behaves like a normal cell but begins to exhibit the properties of a cancer cell. Such 
transformation in the cells makes them self-sufficient in growth signals and resistant to antigrowth 
signals, resulting in uncontainable proliferation. In addition, these cells are able to avoid apoptosis, 
resulting in tumor growth. This whole process of transformation may take 10–20 years. The growth of 
the tumor is aided by angiogenesis, which not only provides nutrition to the tumor but also enables its 
invasion to surrounding tissues, and its metastasis to distant tissues; the latter is usually lethal. 
Figure 1. Roles of the NF-κB-mediated inflammatory pathway in cellular transformation 
and in cancer cell survival, proliferation, invasion, angiogenesis, and metastasis. 
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Inflammation, which occurs as a response to cancer, has two stages, acute and chronic. Acute 
inflammation, the initial stage of inflammation, represents innate immunity; it is mediated through the 
activation of the immune system, lasts for a short period and generally is regarded as therapeutic 
inflammation. If the inflammation persists for a long period of time, however, the second stage, 
chronic inflammation, sets in [4]. Chronic inflammation has been linked with most chronic illnesses, 
including cancer, cardiovascular disease, diabetes, obesity, pulmonary disease, and neurologic 
disease [5], the current review focuses on the role of triterpenoids in targeting inflammatory pathways 
for prevention and treatment of cancer. 
Evidence from tissue culture, animal, and clinical studies suggests that more than 20,000 
triterpenoid-rich fruits are found in nature and have the potential ability to limit the development and 
severity of certain cancers and inflammatory diseases [6]. These triterpenoids, along with their close 
chemical relatives the steroids, are members of a larger family of related structures called 
cyclosqualenoids. Triterpenoids, synthesized in many plants by the cyclization of squalene [7], are 
widely used in Asian medicine. More than 100 prescribed drugs in the United States are obtained from 
natural sources and represent one fourth of the total drugs used. Apart from these drugs that originate 
from natural sources, other phytochemicals also serve as potential drugs after structural 
modification [8]. 
Figure 2. Triterpenoids and their sources. 
 Toxins 2010, 2 
 
2431
Scientific studies have shown triterpenoids to be potential anti-inflammatory and anticancer agents. 
This review covers the anti-inflammatory and anticancer property of triterpenoids originating from 
plants such as onion, ginseng, brahmi, azuma ichirinsou, shallaki, salai guggal, lei gong teng, licorice, 
mango, olive, bearberry, Chinese bellflower, sickle-leaf, tulsi, ashwagandha, and others (Figure 2 and 
Table 1) that target one or more of the various phases of tumorigenesis. As more than 20,000 
triterpenoids are available in nature and it is difficult to describe them all, this review summarizes what 
we know of a few triterpenoids with structural similarity, including avicin, erythrodiol, madecassic 
acid, maslinic acid, momordin, saikosaponins, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid 
(CDDO) and its methyl ester CDDO-Me, platycodon D, withanolide, diosgenin, betulinic acid, 
boswellic acids, pristimerin, and celastrol (Figure 3); their active moieties for anti-inflammatory and 
anticancer activity.  
Figure 3. Chemical structures of different types of triterpenoids that inhibit NF-κB. 
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Table 1. Common medicinally active triterpenoid obtained from plants. 
Chemical Compound   Common Name  Botanical Name 
Tetracyclic triterpenoid     
Astragaloside   Chinese milk vetch   Astragalus membranaceus  
Cucurbitacin   White bryony   Bryonia alba 
Diosgenin   Fenugreek   Trigonella foenum graecum  
Ganoderic acid  Reishi   Ganoderma lucidum 
Ginsenoside   Ginseng   Panax ginseng  
Gypenoside   Jiaogulan   Gynostemma pentaphyllum  
Oleandrin Oleander    Nerium oleander 
Pentacyclic triterpenoid     
Amyrin   Japanese persimmon   Diospyros kaki 
Asiatic acid   Indian pennywort  Centella asiatica 
Avicin  Elegant wattle   Acacia victoriae 
Betulinic acid   Indian jujube  Ziziphus mauritiana 
 Anemone    Anemone raddeana  
 Club  mosses    Lycopodium cernuum 
  Trumpet satinash   Syzygium claviflorum 
Boswellic acid  Boswellia,  Boswellia serrata 
  Frankincense, salai guggal   Boswellia carteri 
Celastrol  Thunder god vine   Tripterygium wilfordii 
Escin Horse  chestnut  Aesculus hippocastanum 
Glycyrrhizin   Licorice   Glycyrrhiza glabra  
18-β-Glycyrrhetinic acid  Licorice   Glycyrrhizia glabra 
Lupeol   Mango   Mangifera indica 
  Three leaved caper   Crataeva nurvala 
Madecassic acid  Indian pennywort, gotu kola  Centella asiatica 
Momordin Burning  bush  Kochia scoparia 
Oleanolic acid   Bearberry   Arctostaphyllos uva-ursi 
 Heather    Calluna vulgaris 
  Three leaved caper   Crataeva nurvala 
 Reishi    Ganoderma lucidum 
 Chinese  elder  Sambucus chinensis 
 Sodom's  apple  Solanum incanum 
Platycodon D   Balloon flower  Platycodon grandiflorum 
Pristimerin  Espinheira santa   Maytenus ilicifolia 
 Pale  Bittersweet  Celastrus hypoleucus 
  Thunder god vine   Tripterygium wilfordii 
Saikosaponins  Hare's ear root, sickle-leaf  Bupleurum falcatum L.  
Ursolic acid   Holy basil, tulsi  Ocimum sanctum L. 
 Thyme  Thymus vulgaris L. 
 Lavender  Lavandula augustifolia 
 Catnip    Nepeta sibthorpii 
 Peppermint  leaves    Mentha piperita L. 
Withanolide  Indian ginseng, ashwagandha  Withania somnifera Toxins 2010, 2 
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The review also focuses on targets for inflammation, proliferation, apoptosis, invasion, metastasis 
and angiogenesis. Because a large portion of these nutraceuticals show great potential for targeting 
cancer through various mechanisms—such as the downregulation of transcription factors (e.g., nuclear 
factor-kappaB [NF-κB]), anti-apoptotic proteins (e.g., bcl-2, bcl-xL), promoters of cell proliferation 
(e.g., cyclooxygenase-2 [COX-2], cyclin D1, c-myc), invasive and metastatic genes (e.g., matrix 
metalloproteinases [MMPs], intracellular adhesion molecule-1 (ICAM-1), and angiogenic protein 
(vascular endothelial growth factor (VEGF)) (Table 2); and other uses of these triterpenoids are shown 
in Table 3. This review summarizes the sources and structures of triterpenoids and provides insight 
into the underlying molecular targets for cancer prevention and therapy. 
Table 2. Molecular targets of triterpenoid for anticancer and anti-inflammatory activities. 
Triterpenoid Targets    References 
Amyrin NF-κB, IL-1β, COX-2, CREB, ERK, PKC, P38 MAPK  [9,10] 
Avicin NF-κB, Fas, STAT3, caspase-8, Bcl-2, Bcl-xL  [11–16] 
Asiatic acid  NF-κB, caspases-2, -3, -8 and -9, PARP, Bcl-2  [17–24] 
Astragaloside NF-κB, VCAM-1   [25] 
Betulinic acid  NF-κB, STAT3, Bax, Bcl-2, Bcl-xL, FAK  [26–38] 
Boswellic acid  NF-κB, STAT3, AR, p21, DR5, caspase-3 and -8  [32,39–48] 
Celastrol NF-κB, IAP1, IAP2, Bcl-2, Bcl-xL, c-FLIP, COX-2, survivin, cyclin 
D1, MMP9, VEGF, iNOS, Hsp90, cdc37, VEGFR 
[49–53] 
Cucurbitacin  Cyclin B1, cyclin D1, Mcl-1, cdc25C, STAT3, p53  [54–59] 
Diosgenin NF-κB, survivin, XIAP, cyclin D1, cdk-2, cdk-4, mTOR, JNK, HMG-
CoA reductase, p53, AIF, p21 ras, β-catenin  
[60–65] 
Escin NF-κB, STAT3, JAK2, cyclin D1, Bcl-2, Bcl-xL, survivin, Mcl-1, 
VEGF, COX-2, MMP9 
[66,67] 
Ganoderic acid  NF-κB, AP-1, NFATc1, cdk4, uPA, MMP2, MMP9,  [68–72] 
Ginsenosides NF-κB, Bax, caspase-3, caspase-8, Bcl-2, IAP, XIAP, cyclin B1, 
cyclin D, cdk2, cdk4, VEGF, MAPK, IL-1β, TNF-α, ICAM-1, JNK 
[73–76] 
Glycyrrhizin NF-κB, AP-1, TLR2, COX-2, IL-1α, TNF-α   [77–83] 
Glycyrrhetinic 
acid 
NF-κB, H-ras, Bax, cytochrome C, Bcl-2, Bcl-xL, Bak, caspase-3, 
PPARγ 
[84–86] 
Gypenoside NF-κB, PPAR , VCAM-1, TF, iNOS, Ras  [87–92] 
Lupeol NF-κB, cFLIP, survivin, Bax, caspase-3, caspase-9  [93–102] 
Madecassic 
acid 
iNOS, COX-2, TNF-α, IL-1, IL-6  [103] 
Momordin NF-κB, AP-1, Bcl-2, Bax, caspase-3, PARP   [104,105] 
Oleandrin NF-κB, AP-1, Fas, ERK, Akt, FGF-1  [106–110] 
Oleanolic acid  NF-κB, mTOR, caspases-3, -8, and -9, ICAM-1, VEGF, PARP, Akt  [111–114] 
Platycodon D  NF-κB, Egr-1, caspase-3  [115,116] 
Pristimerin NF-κB, PARP-1, JNK, Bax, p27, Bcl-2, Bcl-xL  [117–120] 
Saikosaponins NF-κB, NF-AT, AP-1, IL-6, TNF- , IFN- , PKC , JNK, p53, Fas/FasL  [121–123] 
Ursolic acid  NF-κB, STAT3, Bcl-2, Bax, ICAM-1, p53, PKC  [114,124–132] 
Withanolide NF-κB, AP-1, IL-6, COX-2, Hsp70, Hsp90, Bax  [133–138] 
AIF, apoptosis inducing factor; AMPK, 5' AMP-activated protein kinase; AP-1, activator protein-1; Apaf1, 
apoptotic protease activating factor 1; AR, androgen receptor; Bax, BCL2-associated X protein; Bfl-1/A1, 
BCL2-related protein A1; cdc, cell division cycle; cdk, cyclin-dependent kinase; cFLIP, cellular FLICE Toxins 2010, 2 
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inhibitory protein; COX-2, cyclooxygenase-2; CREB, cAMP response element binding protein; DR, death 
receptor; EGFR, epidermal growth factor receptor; Egr-1, earyl growth response factor-1; ERK, extracellular 
signal-regulated kinase; FAK, focal adhesion kinase; FasL, Fas-ligand; FGF-1, fibroblast growth factor-1; 
GSK3β, glycogen synthase kinase-3β; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; Hsp, heat 
shock protein; IAP, inhibitor of apoptosis protein; ICAM-1, intercellular adhesion molecule-1; IFN-γ, 
interferon-γ; IL-1, interleukin-1; iNOS, inducible nitric oxide synthase; JNK, c-Jun N-terminal kinase; 
MAPK, mitogen-activated protein kinase; Mcl-1, myeloid cell leukemia-1; MCP, monocyte chemotactic 
protein; MEK, MAPK/ERK kinase, MIP-2, macrophage-inflammatory protein-2; MMP, matrix 
metalloproteinase; mTOR, mammalian target of rapamycin; NF-AT, nuclear factor of activated T-cells; 
NF-κB, nuclear factor-kappa B; PARP, poly (ADP-ribose) polymerase; PI3K, phosphoinositide-3 kinase; 
PKC, protein kinase C; PPAR, peroxisome proliferator-activated receptor; Sp1, specificity protein 1; STAT3, 
signal transducer and activator of transcription 3; TF, tissue factor; TLR2, Toll-like receptor-2; TNF-α, tumor 
necrosis factor-α; TRAF1, TNF receptor-associated factor-1; uPA, urokinase-type plasminogen activator; 
VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor; VEGFR, VEGF 
receptor; XIAP, X-linked IAP.  
Table 3. Other uses of triterpenoid in treatment of chronic diseases. 
Disease Triterpenoid 
Diabetes  Astragaloside, Cucurbitacin, Diosgenin, Ginsenoside, Amyrin, Asiatic acid, Avicin, 
Betulinic acid, Escin, Glycyrrhizin, Oleanolic acid, Platycodon D, Ursolic acid, 
Withanolide 
Cardiovascular Astragaloside,  Cucurbitacin, Diosgenin, Ginsenoside, Gypenoside, Oleandrin, 
Betulinic acid, Escin, Glycyrrhizin, Lupeol, Oleanolic acid, Platycodon D, 
Saikosaponins, Ursolic acid, Withanolide 
Arthritis    Cucurbitacin, Diosgenin, Ginsenoside, Amyrin, Boswellic acid, Celastrol, 
Glycyrrhizin, Lupeol, Oleanolic acid, CDDO-Me, Ursolic acid, Withanolide, 
Atherosclerosis  Diosgenin, Gypenoside, Betulinic acid, Glycyrrhizin, Oleanolic acid, Ursolic acid 
Obesity  Diosgenin, Ginsenoside, Betulinic acid, Escin, Glycyrrhizin, Platycodon D, 
Momordin, Oleanolic acid, Ursolic acid 
Alzheimer CDDO-MA,  Alpha-onocerin 
Parkinson   CDDO-MA 
Multiple 
sclerosis 
Oleanolic acid 
Depression  Asiatic acid  
Osteoporosis Ursolic  acid 
Cerebral 
ischemia 
Escin, Asiatic acid 
Memory loss  CDDO-MA 
2. Source and Structure of Triterpenoids 
Triterpenoids are metabolites of isopentenyl pyrophosphate oligomers that are chemically related to 
squalene, which is a large group of compounds having 30 carbon atoms arranged in five rings with 
several oxygen atoms attached. Triterpenoids are part of the largest group of plant products, Saponins 
can be chemically biosynthesized when one or more sugar moieties attach to aglycone. There are two 
types of saponins, steroidal aglycone and triterpenoid aglycone. Both steroid and triterpenoid systems Toxins 2010, 2 
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are found to be biosynthesized from a common precursor such as squalene [139]. Triterpenoids are 
synthesized from isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate 
(DMAPP). For this cyclization, three prenyltransferases synthesize the linear prenyl pyrophosphates 
geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate 
(GGPP). Squalene is in turn derived biosynthetically by the cyclization of a number of units of 
isoprene, (C5H8)n, which undergo folding through 20 different patterns in the presence of prenyl 
pyrophosphates to form monocyclic, dicyclic, tricyclic, tetracyclic, or pentacyclic derivatives [140]. A 
family of oxidosqualene cyclases may produce only a single product, such as lupeol cyclases, but there 
are also multifunctional oxidosqualene cyclases that use dammarenyl cation intermediates to produce 
many products. Once squalene undergoes cyclization, it goes through the cytosolic mevalonate 
pathway to make a proximate tetracyclic C30 compound, lanosterol (Figure 4), which further 
undergoes oxidation and catabolic metabolism to form cholesterol.  
Figure 4. Different patterns of cyclization of squalene to form triterpenoids. 
(IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate). 
 
The variety of triterpenoids in nature is a result of the evolution of a large terpene synthase 
superfamily. One study analyzed the amino acid sequences of terpene synthase genes and found that 
all originated from an ancestral diterpene synthase. It was also found that the diversity of these 
triterpenoids is due to the structural features of their catalyst enzymes. Terpenes and their metabolites 
are widely distributed in various plant systems that depend on various biotic and abiotic environmental 
factors. Terpenes and their metabolites are used in several developmental and physiological functions 
on the basis of the differential expression profiles of terpene synthase genes. Terpenes and their 
metabolites play a very important role in a plant’s defense mechanism. They protect the plants from 
both constitutive and induced defensive responses against insects and environmental stress [141,142]. 
Hence, triterpenoids provide a very good protection shield for plants, indicating their potential for use 
in the prevention of various cancers and inflammatory diseases in humans.  
3. Molecular Targets of Triterpenoids 
In 1856, Rudolf Virchow for the first time showed inflammation to be a predisposing factor for 
various types of cancer. Today, the data suggest that at least one in seven malignant tumors diagnosed 
worldwide results from chronic inflammation and infection. Recognition of this fact has led to greater Toxins 2010, 2 
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interest in research for molecular targets involved in the inflammatory pathways that trigger cancer and 
to find novel markers that restrain cancer progression along these pathways. 
The conventional methods of treatment of cancer include surgery, chemotherapy and/or 
radiotherapy; the mode of treatment depends largely upon the type of cancer the patient has. 
Innovative, so-called multitargeting therapies from natural resources are urgently needed to target the 
various steps of cancer progression or the processes involved in cancer cell survival and metastasis to 
other parts of the body.  
It is clear now that cancer is not a simple disease involving a single gene, but a complex disease 
involving interaction between multiple genes, either within the same cell or with those of neighboring 
tissues. The prevention or progression of human cancer depends on the integrity of a complex network 
of defense mechanisms in which 300–500 genes have gone wrong, leading to the upregulation of 
undesired products such as antiapoptotic proteins or the downregulation of tumor suppressor proteins.  
3.1. NF-κB 
NF-κB, a ubiquitous transcription factor, was discovered in 1986 as a nuclear factor that binds to 
the enhancer region of the κB chain of immunoglobulin in B cells. It is present in all cells, and in its 
resting stage, this factor resides in the cytoplasm as a heterotrimer consisting of p50, p65, and 
inhibitory subunit IκBα. NF-κB is activated by free radicals, inflammatory stimuli, cytokines, 
carcinogens, tumor promoters, endotoxins, γ-radiation, ultraviolet light, and x-rays  [143]. On 
activation, the IκBα protein, an inhibitor of NF-κB, undergoes phosphorylation, ubiquitination, and 
degradation. p50 and p65 are then released to be translocated to the nucleus, bind to specific DNA 
sequences present in the promoters of various genes, and initiate the transcription of more than 400 
genes. The kinase that causes the phosphorylation of IκBα is called IκBα kinase (IKK). Whereas the 
IKKβ mediates the classic/canonical NF-κB activation pathway, the IKKκ mediates the noncanonical 
pathway. IKK itself must be activated before it can activate IκBα. More than a dozen kinases have 
been described that can activate IKK, including protein kinase B (Akt), mitogen-activated 
protein/extracellular signal-regulated kinase kinase 1 (MEKK1), MEKK3, transforming growth factor 
(TGF)–activating kinase 1 (TAK1), NF-κB–activating kinase, NF-κB–inducing kinase, protein 
kinase C, and the double-stranded RNA-dependent protein kinase (PKR). 
3.2. STAT3 
Signal transducer and activator of transcription 3 (STAT3), one of the major molecular targets of 
triterpenoids, was first identified in 1994 as a DNA-binding factor that selectively binds to the 
IL-6-responsive element in the promoter. The activation of STAT3 is regulated by the phosphorylation 
of tyrosine 705 by receptor and nonreceptor protein tyrosine kinases, including epidermal growth 
factor receptor (EGFR) kinase [144], Src  [145], Janus-activated kinases (JAK) [146,147], and 
extracellular signal-regulated kinase (ERK) [148]. The phosphorylation of STAT3 in the cytoplasm 
leads to its dimerization, translocation into the nucleus, and DNA binding, which results in the 
regulation of several genes involved in cell proliferation, differentiation, and apoptosis. 
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3.3. Other Pathways 
A large body of evidence signifies the role of inflammation in cancer development through 
mediators such as reactive oxygen species (ROS), free radicals, and inflammatory cytokines like tumor 
necrosis factor-α (TNFα), lymphotoxins, and angiogenic factors. Also known to influence oncogenesis 
are signaling pathways that in normal cells are involved in tissue homeostasis, such as the NF-κB, 
prostaglandin/cyclooxygenase-2 (COX-2), and p53 pathways; the DNA repair machinery; and a family 
of the Toll-like receptor proteins. 
Some of the most commonly known molecular targets of triterpenoids involved in the treatment and 
prevention of cancer have been targeted according to comprehensive knowledge of tumor growth and 
metastasis. This approach will maximize the effect of triterpenoids and minimize side effects by 
multitargeting the cells or processes that enable cancer to survive and spread in humans.  
4. Role of Triterpenoids in Cancer Prevention 
4.1. Role of Triterpenoids in Inflammation  
Inflammation is derived from the Latin word ‘inflammare or inflammatio’, which means, “to set on 
fire.” Inflammation is a basic defense mechanism in which the body reacts against infections, 
irritations, or other injuries. The four key features of inflammation are redness, heat, swelling, and 
pain. Inflammation stimulates the immune response at the site of injury or infection and is itself 
stimulated by increases in blood supply and vascular permeability, which allow more infiltration of 
plasma and leukocytes from the blood into injured tissues. This particular type of immune response is 
important because it helps the body to ward off pathogens and also to initiate the healing process in the 
damaged tissues. This reaction is classified as acute inflammation. Studies have shown that chronic 
inflammation is a progenitor of tumor progression and that many cancers have been found to arise 
from sites of infection, chronic irritation, and inflammation. Inflammation orchestrates the 
microenvironment around tumors and allows them to progress by fostering proliferation, survival, and 
migration  [149]. The inflammatory cells and the network of signaling molecules provided by the 
inflammatory microenvironment are necessary for the malignant progression of transformed cells.  
Inflammation promotes tumor development through both nonimmune and immune. NF-κB is a 
central transcription factor mediating inflammatory and innate immune responses. NF-κB may be 
activated by various factors, including cytokines, microbial pathogens, and oxidative, genotoxic, 
physiological, or chemical stress factors. In addition to these, proinflammatory cytokines and chronic 
infections can play an important role in the stimulation of IKK activity, which leads to constitutive 
NF-κB activation [150–152]. The activation of NF-κB through IKKβ plays a major role in 
inflammation induced tumor promotion and progression. Various proinflammatory factors like TNFα 
and Toll-like receptor ligands such as lipopolysaccharide (LPS) normally activate these 
pathways [153]. This activation signals the transcription of various cancer-promoting genes such as 
antiapoptotic genes, proangiogenic genes, and proinvasion genes  [154]. NF-κB DNA binding is 
thought to result in the activation of a number of genes that lead to inflammatory diseases like 
Alzheimer disease and arthritis in addition to cancer [143]. Toxins 2010, 2 
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Along with NF-κB, factors such as TNF and interleukins (IL-1β, IL-6, and IL-8) also serve as 
connecting links between inflammation and cancer. TNF is released mainly from macrophages and 
regulates immune cells. Its dysregulation and overproduction lead to cancer and other diseases. TNF 
also plays a role in the activation of NF-κB by binding to a TNF receptor present on the cell surface 
that in turn triggers a pathway that leads to the activation of IKK [3]. Interleukins are a group of 
cytokines released in the body from numerous cells in response to various stimuli. While IL-1β plays 
an important role in the inflammatory response against infection by increasing the expression of 
endothelial adhesion factors, thus allowing infiltration of leukocytes at the site of infection, IL-6 is a 
proinflammatory cytokine released in response to trauma or tissue damage. IL-8, a member of the 
CXC chemokine family also known as CXCL8, can function as a mitogenic, angiogenic, and 
mutagenic factor promoting cancer progression [155]. 
Inflammatory cells and their regulators are found to facilitate angiogenesis and promote the growth, 
invasion, and metastasis of tumor cells [156]. Normal levels of some enzymes like inducible nitric 
oxide synthase (iNOS) and COX-2 play an essential role in the physiological protective response to 
tissue injury, but if expressed in excessive amounts, these inflammatory enzymes may cause 
carcinogenesis [149,157,158]. In tumor tissue, levels of prostaglandins (PGs) are often elevated. PGs 
are endogenous mediators of inflammation and are formed from arachidonic acid by constitutive 
COX-1 and inducible COX-2. Production of higher levels of PGs is thought to cause cellular injury 
and ultimately lead to carcinogenesis by inhibiting apoptosis, stimulating cellular proliferation, and 
promoting angiogenesis and tumor invasiveness  [159]. Cycloartane triterpenoids from Cimicifuga 
dahurica suppressed the expression of cdc2 and COX-2 protein. These results imply that triterpenoids 
possess potential antitumor activities and exert their cytotoxicity through apoptosis and G2/M cell 
cycle arrest [146].  
Many triterpenoids derived from botanical sources play an important role in reducing inflammation. 
These include avicin, asiatic acid, astragaloside, betulin, betulinic acid, boswellic acid, celastrol, 
cucurbitacin, diosgenin, erythrodiol, ganoderiol, ginsenosides, glycyrrhizin, glycyrrhetinic acid, 
gypenoside, lupeol, madecassic acid, maslinic acid, oleandrin, oleanolic acid, platycodon D, 
pristimerin, saikosaponins, ursolic acid, and withanolide (Table 2). Many of these triterpenoids target 
NF-κB, leading to its downregulation. 
Pentacyclic triterpenoids have been found to have many functions, although their effective 
concentrations for various cellular effects may vary widely. Depending upon the dose administered, 
triterpenoids can induce anti-inflammatory, cytoprotective, tumor-differentiating, 
proliferation-arresting, and apoptotic effects  [160–162]. The anticancer activities of triterpenoids 
appear to be mediated, at least in part, by their common ability to block TNF-induced NF-κB 
activation by inhibiting IKKβ [163,164]. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oyl] imidazole (CDDO-Im) blocks NF-κB activation through direct inhibition of 
IKKβ  [35]. This is evident from the fact that the molecular targets of the synthetic oleanane 
triterpenoids include IKK and also pathways involving STAT, IL-6, TGF-β, and KEAP1 (the inhibitor 
of the transcription factor Nrf2). Inhibition of multiple targets by triterpenoids is believed to be 
mediated by the promiscuous reversible Michael addition of these compounds to exposed nucleophilic 
groups (such as accessible cysteine sulfides) of various susceptible signaling proteins  [165]. 
Triterpenoids affect multiple signaling pathways, and the clinical properties of triterpenoids, Toxins 2010, 2 
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particularly those of pentacyclic triterpenoids, have been shown in various studies. The structure-
activity relationships indicate that the presence of α,β-unsaturated carbonyl moieties significantly 
enhance the potency of these pentacyclic triterpenoids. Of the 12 pentacyclic triterpenoids, four 
(CDDO, CDDO-Me, pristimerin, and celastrol) have been shown to be potently and selectively lethal 
to different cancer cells and show a several fold increase in anti-inflammatory activity. This action is 
caused by the α,β-unsaturated carbonyl in ring A. The incorporation of a cyano and keto group within 
this enone moiety further enhances its efficacy and potency. 
Avicins are electrophilic pentacyclic triterpenoids with proapoptotic, anti-inflammatory, and 
antioxidant properties derived from Acacia victoriae. Avicins have been shown to induce 
redox-dependent post-translational modification of cysteine residues to regulate protein function, 
which downregulate both STAT3 activity and the expression of STAT3-regulated prosurvival proteins 
and contribute to the induction of apoptosis in vitro [166]. Avicins were found to be potent inhibitors 
of TNF-induced NF-κB and to slow the accumulation of the p65 subunit of NF-κB in the nucleus; 
however, the degradation of IκBα was unaffected. In addition Avicins blocked the binding of NF-κB 
to DNA in in vitro binding assays. Treatment of cells with dithiothreitol (DTT) totally reversed the 
avicin G-induced inhibition of NF-κB activity, suggesting that sulfhydryl groups critical for NF-κB 
activation were being affected. Avicin G treatment decreased the expression of NF-κB regulated 
proteins such as iNOS and COX-2 [16]. Other studies showed that pretreating cells with triterpenoids 
for 24 hours significantly reduced the induction of NF-κB mediated through TNF-α [44,167].  
Pristimerin, a natural triterpenoid, elicits cellular responses closely resembling those elicited by 
proteasome inhibitors, such as the rapid induction of heat shock proteins (HSPs), activating 
transcription factor 3 (ATF3), and C/EBP homologous protein (CHOP). Pristimerin also inhibits 
NF-κB activation by inhibiting IKK-α or IKK-β, whereas proteasome inhibitors instead suppress 
NF-κB function by impairing the degradation of ubiquitinated IκB. By inhibiting both IKK and the 
proteasome, pristimerin suppresses the activation of constitutive NF-κB in myeloma cells. Multiple 
myeloma is exquisitely sensitive to proteasome or NF-κB pathway inhibition. Consistent with this, 
pristimerin has been shown to be potently and selectively lethal to primary myeloma cells 
(IC50 < 100 nM) and to inhibit xenografted plasmacytoma tumors in mice [118]. Pristimerin is also 
known as an antifungal, antimicrobial, and anti-inflammatory plant compound with an effect on the 
iNOS system in LPS-activated RAW 264.7 macrophages [168].  
Celastrol, a natural triterpenoid with a structure similar to that of pristimerin, is found in the thunder 
god vine and was identified as having potential for use in cancer treatment because of its ability to 
enhance the death of melanoma cells. Celastrol also inhibited cell proliferation in melanoma cells. 
When celastrol was used to treat melanoma cells, it (like pristimerin) increased levels of ubiquitinated 
proteins, reduced levels of TNF-α-induced IκB phosphorylation, and blocked NF-κB translocation to 
the nucleus at nanomolar concentrations; however, the molecular mechanism for these effects differed. 
Celastrol normally inhibits LPS-induced phosphorylation of mitogen-activated protein 
kinases/extracellular signal-regulated kinases 1/2 (MAPK/ERK1/2) and the DNA binding activity of 
NF-κB [49]. Other studies have indicated that TNF-induced IKK activation requires the activation of 
TAK1 and that celastrol inhibits the TAK1-induced NF-κB activation [52]. Celastrol also suppressed 
the ovalbumin-induced airway inflammation, hyperresponsiveness, and tissue remodeling by 
regulating the imbalance of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and tissue inhibitor of Toxins 2010, 2 
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metalloproteinase 1 and 2 (TIMP1 and TIMP2) by inflammatory cytokines through MAP kinases and 
NF-κB in inflammatory cells. 
The triterpenoids erythrodiol and madecassic acid are structural analogues of each other and have 
antiproliferative and anticancer activity. However, only madecassic acid has also shown 
LPS-stimulated NF-κB inhibition with subsequent blocking of p65 protein translocation to the 
nucleus [103]. This may be because of the presence of an additional hydroxyl at carbon 2, which play 
an important role in the electrophilic reaction. Maslinic acid, which is similar to madecassic acid, also 
inhibits NF-κB translocation. Maslinic acid also inhibited p50, p65, and NF-κB translocation in a 
dose-dependent manner in both unstimulated and phorbol-myristate acetate (PMA)-challenged cells, 
being particularly effective on the p50 subunit [169]. Momordin, an analogue of maslinic acid, does 
not contain any hydroxyl group at the carbon 2 position but still it has shown NF-κB inhibition in 
osteoclast differentiation. This may be because of momordin’s action on c-Fos, a component of the 
activating protein-1 (AP-1) transcription factor that plays a key role in osteoclast differentiation. 
Momordin inhibited the activation of NF-κB as well as AP-1 in receptor activator of NF-κB ligand 
(RANKL)-induced RAW264.7 cells, in which momordin appeared to target IκB degradation and c-Fos 
expression, but not MAPK signaling pathways [104].  
Saikosaponins are triterpene saponins derived from the medicinal plant Bupleurum falcatum L. 
(Umbelliferae) that have shown various pharmacological and immunomodulatory activities including 
anti-inflammatory, antibacterial, antiviral and anticancer effects in ACHN, C32, Caco-2 , A375, A549, 
and Huh-7D12 cell lines [170]. Studies demonstrated that saikosaponins not only suppressed the 
proliferation of human T cells costimulated with OKT3 and CD28 but also inhibited PMA-, 
PMA/ionomycin-, and concanavalin A-induced mouse T-cell activation in vitro. This inhibitory effect 
of saikosaponins on PMA-induced T-cell activation was associated with the downregulation of NF-κB 
signaling through the suppression of IKK and Akt activities. Saikosaponins also suppressed both the 
DNA binding activity and the nuclear translocation of nuclear factor of activated T cells (NF-AT) and 
AP-1 in the PMA/ionomycin-stimulated T cells. In addition, the cell surface markers like IL-2 receptor 
(CD25) were also downregulated, and the production of proinflammatory cytokines such as IL-6, 
TNF-α, and interferon (IFN)-γ was decreased. These results indicate that the NF-κB, NF-AT, and 
AP-1 (c-Fos) signaling pathways are involved in the T cell inhibition evoked by saikosaponins, 
demonstrating their potential for treating T cell-mediated autoimmune conditions [123]. Another study 
showed that saikosaponins have direct involvement in p53-, NF-κB- and Fas/Fas ligand-mediated 
induction of apoptosis and cell cycle arrest in human hepatoma cell lines. Saikosaponins also inhibited 
cell survival signaling by enhancing the amount of IκBα in the cytoplasm and reducing the level and 
activity of NF-κB in the nucleus, and subsequently attenuated the expression of bcl-xL in HepG2 and 
Hep3B cells. Saikosaponins therefore decreased cell proliferation and induced apoptosis both in 
p53-positive HepG2 and p53-negative Hep3B cells [121].  
Diosgenin, a steroidal triterpenoid having two pentacyclic rings, is present in Trigonella foenum 
graecum and other plants and has been shown to suppress inflammation, inhibit proliferation, and 
induce apoptosis in a variety of tumor cells. Diosgenin inhibits osteoclastogenesis, invasion, and 
proliferation through the downregulation of Akt, IKK activation, and NF-κB-regulated gene 
expression. Diosgenin suppresses NF-κB through direct DNA binding, activation of IKK, IκBα 
phosphorylation, IκBα degradation, p65 phosphorylation, and p65 nuclear translocation by inhibiting Toxins 2010, 2 
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Akt activation. NF-κB-dependent reporter gene expression was also abrogated by diosgenin  [64]. 
Similar activity was found in Withania somnifera, also known as Indian ginseng, which is widely used 
in the Ayurvedic system of medicine to treat tumors, inflammation, arthritis, asthma, and hypertension. 
Chemical investigation of the roots and leaves of this plant has yielded bioactive withanolides, a group 
of C28-steroidal lactone triterpenoids. Withania somnifera inhibits COX enzymes, lipid peroxidation, 
and proliferation of tumor cells, and it potentiates apoptosis, inhibits invasion, and abolishes 
osteoclastogenesis through the suppression of NF-κB activation and NF-κB-regulated gene 
expression [135].  
Ursolic acid is a pentacyclic triterpene compound isolated from many types of medicinal plants and 
widely present in the human diet. It has been reported to possess a wide range of pharmacological 
properties and is one of the most promising chemopreventive agents for cancer. It has been shown to 
suppress the expression of several genes associated with tumorigenesis. It suppressed NF-κB 
activation induced by various carcinogens including TNF, PMA, okadaic acid, hydrogen peroxide 
(H2O2), and cigarette smoke condensate. Ursolic acid inhibited DNA binding of NF-κB. Ursolic acid 
inhibited IκBα degradation, IκBα phosphorylation, IKK activation, p65 phosphorylation, p65 nuclear 
translocation, and NF-κB-dependent reporter gene expression. Ursolic acid also inhibited   
NF-κB-dependent reporter gene expression activated by TNF receptor (TNFR), TNFR-associated 
death domain (TRADD), TNFR-associated factor (TRAF), NF-κB-inducing kinase (NIK), IKK, and 
p65  [125]. CDDO and CDDO-Me, two potent oleanane triterpenoids having structures similar to 
ursolic acid, are currently in Phase I clinical trials for the treatment of leukemia and solid tumors. 
CDDO blocks the action of NF-κB by preventing the nuclear translocation of p65; this blocks the 
transactivation of the NOS2 and PTGS2 genes, thus playing an anti-inflammatory role and causing cell 
cycle arrest. Cucurbitacin combined with CDDO has been shown to bring about apoptosis by 
inhibiting NF-κB activation, IκBα phosphorylation and degradation, NF-κB-reporter gene expression 
induced by TNF, and STAT signaling. Some other triterpenoids like astragaloside, boswellic acids, 
celastrol, ganoderiol F, and gypenoside also blocked the action of NF-κB, inhibiting the transactivation 
of cox-2 [44,51,171−173]. CDDO, at nanomolar concentrations, suppresses the de novo synthesis of 
the inflammatory enzymes iNOS and COX-2 in activated macrophages because they contain 
α,β-unsaturated carbonyl moieties. Since iNOS and COX-2 overexpression have been implicated as 
possible enhancers of carcinogenesis, CDDO has potential to be used as a chemopreventive agent. 
Furthermore, CDDO may also serve as a chemotherapeutic agent, as micromolar to nanomolar 
concentrations effectively induced differentiation of human myeloid leukemia cells, inhibited the 
proliferation of various human tumor cell types, and induced apoptosis in human myeloid and 
lymphocytic leukemia cells, osteosarcoma cells, and breast cancer cells, including cell lines resistant to 
chemotherapy [160]. 
Boswellic acids, a type of pentacyclic triterpenoid, have been shown to induce apoptosis in different 
cancer cells. At the molecular level, these compounds inhibit constitutively activated NF-κB signaling 
by intercepting the IKK activity; signaling through the IFN-stimulated response element remained 
unaffected, suggesting specificity for IKK inhibition [45,46]. In a xenograph study of animal 
meningioma cells, boswellic acids were found to have potent cytotoxic activity with IC50 values in the 
range of 2–8 μM. At low micromolar concentrations, boswellic acids rapidly and potently inhibited the 
phosphorylation of ERK-1/2 and impaired the motility of meningioma cells stimulated with platelet Toxins 2010, 2 
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derived growth factor (PDGF) BB. The cytotoxic action of boswellic acids on meningioma cells may 
be mediated, at least in part, by the inhibition of the ERK signal transduction pathway, which plays an 
important role in signal transduction and tumorigenesis [174]. 
Platycodon, a triterpenoid isolated from Platycodon grandiflorum, showed chemopreventive effects 
on tumor invasion and migration in HT-1080 tumor cells. Platycodon reduced PMA-enhanced MMP9 
and MMP2 activation in a dose dependent manner. Platycodon suppressed PMA enhanced expression 
of MMP9 protein as well as mRNA and transcription activity levels through the suppression of NF-κB 
activation without changing the TIMP1 levels. Platycodon also reduced PMA-enhanced expression of 
MMP2 active forms through the suppression of membrane-type 1 MMP (MT1-MMP), but platycodon 
did not alter MMP2 and TIMP2 levels. Moreover, ROS production induced by PMA was partly 
decreased in the presence of platycodon, and this suppression of ROS production may be related to 
diminished NF-κB activity [175]. In this case, NF-κB inhibition is totally ROS mediated, and most of 
these ROS are released from glucose molecules that are present on the side chain. Platycodon has been 
shown to be cytotoxic and to inhibit telomerase activity by downregulating hTERT expression at 
concentrations between 10 and 20 μM. Platycodon also reduced c-Myc and SP1 protein levels and 
DNA binding activities in a dose-dependent manner [176] and suppressed the LPS-induced expression 
of iNOS and COX-2 genes by suppressing NF-κB activation at the transcriptional level [51]. 
Platycodon also enhanced the mRNA expression of cytokines IL-2, IFN-γ, IL-4, and IL-10 and 
transcription factors T-bet and GATA-3 in mice splenocyte induced by concanavalin A. This suggests 
that the number of sugar residues in the glycosidic chains attached to C-3 of aglycone could affect the 
hemolytic and adjuvant activities of platycodigenin-type saponins  [177]. Betulinic acid suppressed   
NF-κB-dependent reporter gene expression and the production of NF-κB-regulated gene products such 
as COX-2 and MMP9, which are induced by inflammatory stimuli. It also suppressed TNF-induced 
apoptosis through the activation of NF-κB and NF-κB-regulated gene expression induced by 
carcinogens and inflammatory stimuli [35]. 
4.2. Role of Triterpenoids in Tumor Cell Survival, Apoptosis, and Proliferation 
Apoptosis, which in Greek literally means “falling away,” is a process of programmed cell death 
that occurs normally in multicellular organisms. Apoptosis is a natural, organized process that plays an 
important role in embryonic development and adult tissue equilibrium by adjusting the physiological 
processes involved. The human body is made up of six trillion cells, with approximately three billion 
cells replaced every minute. Through the process of apoptosis, the body can eliminate damaged or 
unneeded cells without local inflammation from the leakage of cell contents [178].  
Because deregulation of apoptosis is one of the most important factors involved in tumor cell 
progression, a number of scientific studies have been done on this process to determine if it can be 
exploited in cancer treatment. Apoptosis is the human body’s mechanism for destroying any cell that 
has abnormalities such as DNA damage, oncogene activation, nutrient deficiency, or hypoxia. But 
cancer cells have the ability to escape apoptosis, allowing tumors to grow rapidly and uncontrollably.  
Apoptosis in cancer cells can be triggered by the activation of proteases such as caspases, leading to 
the cells’ destruction. There are two different pathways by which this apoptosis can be stimulated in 
cancer cells. The first is the intrinsic pathway through mitochondria, which releases cytochrome C Toxins 2010, 2 
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proteins such as second mitochondria derived activator of caspases (SMACs) that bind to and 
deactivate inhibitor of apoptosis proteins (IAPs), allowing apoptosis to proceed. Apoptotic signals in 
this pathway may come in the form of members of the Bcl-2 family of proteins such as pro-apoptotic 
Bax, which can be upregulated by tumor suppressor protein p53 in response to DNA damage [179]. 
The second pathway is the extrinsic pathway, in which apoptosis is triggered by the activation of 
proapoptotic receptors such as death receptors 4 and 5 (DR4 and DR5) and Fas, which are present on 
the cell surface. The activation of the death receptor pathway leads to receptor aggregation, which then 
initiates the recruitment and activation of initiator caspase-8. While p53 is involved in the intrinsic 
pathway, it has no role in the extrinsic pathway [178,180–182]. 
STAT3 activation has been associated with cell survival, proliferation, and invasion in various 
human cancers. Some members of the Bcl-2 family of proteins, such as Bcl-2 and Bcl-xL, also play a 
role in apoptosis and have been found to be elevated in different types of cancer cells. These proteins 
cause some cells to develop resistance to drugs used in cancer treatment. Another protein, survivin, 
may play a role in tumor progression as it has been found at excessive levels in cancer cells. Targets 
for the treatment of cancer could be those that cause downregulation of the Bcl-2, Bcl-xL, and survivin 
proteins and upregulation of the p53, Bax, and caspase proteins. 
Triterpenoids have been found to act through the intrinsic apoptosis pathway to prevent tumor 
progression. For example, many spice derived triterpenoids have been shown to induce apoptosis in 
different types of cancer cells through a wide variety of mechanisms. Among the most important of 
these are asiatic acid, astragaloside, celastrol, cucurbitacin, diosgenin, gypenoside, hederagenin, 
lupeol, and momordin (Table 2). These triterpenoids have a common target, the antiapoptotic protein 
Bcl-2, which can induce apoptosis in cancer cells. 
Pristimerin has been shown to induce mitochondrial cell death in human cancer cells, and the ROS 
dependent activation of both Bax and poly (ADP-ribose) polymerase-1 (PARP-1) is critically required 
for mitochondrial dysfunction [117,183]. In human HL-60 cells, pristimerin also showed 
antiproliferative effects, with an IC50 of 0.88 μM [184]. In addition to this, pristimerin showed that 
c-Jun N-terminal kinase (JNK) was involved in ROS-dependent Bax activation, which increases 
intracellular ROS, JNK activation, conformational change, and mitochondrial redistribution of Bax, 
mitochondrial membrane potential loss, and cell death. Pretreatment with pristimerin also activated 
PARP-1 [117]. Another study showed that pristimerin induced apoptosis by targeting the proteasome 
in prostate cancer cells. This may be because of the accumulation of ubiquitinated proteins and three 
proteasome target proteins, Bax, p27 and IκBα, in androgen receptor (AR)-negative PC-3 prostate 
cancer cells, which supports the conclusion that proteasome is inhibited by pristimerin [120]. Another 
study showed that this apoptosis might be induced by pristimerin through the direct effect of caspase 
on mitochondria in MDA-MB-231 cells [119]. Pristimerin showed antiviral activity by inhibiting the 
viral DNA synthesis but had no virucidal effect [185].  
Celastrol combined with TNF-related apoptosis-inducing ligand (TRAIL/APO-2L) exerted strong 
synergistic antiproliferative effect against human cancer cells, including those from ovary cancer 
(OVCAR-8), colon cancer (SW620), and lung cancer (95-D). In vivo, the  antitumor efficacy of 
TRAIL/APO-2L was dramatically increased by celastrol. These enhanced anticancer activities were 
accompanied by the prompt onset of caspase-mediated apoptosis. Celastrol also suppressed the 
TNF-induced expression of various gene products involved in antiapoptosis (IAP1, IAP2, Bcl-2, Toxins 2010, 2 
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Bcl-xL, c-FLIP, and survivin), proliferation (cyclin D1 and COX-2), invasion (MMP9), and 
angiogenesis (VEGF) [52].  
Diosgenin-induced apoptosis was associated with COX-2 upregulation in HEL cells [75]. 
Diosgenin also downregulated gene products involved in cell proliferation (cyclin D1, COX-2, and 
c-myc) and antiapoptosis (IAP1, Bcl-2, Bcl-xL, Bfl-1/A1, TRAF1, and cFLIP) [64]. 
  Avicins are novel plant derived metabolites that lower energy metabolism in tumor cells by 
targeting the outer mitochondrial membrane Avicins dephosphorylated STAT3 in a variety of human 
tumor cell lines, leading to a decrease in the transcriptional activity of STAT3. The expression of 
STAT3-regulated proteins such as c-myc, cyclin D1, Bcl-2, survivin, and VEGF were reduced in 
response to avicin treatment. Avicin also induced dephosphorylation of STAT3, dephosphorylation of 
JAKs, and activation of protein phosphatase-1 [11]. Another study showed that avicins induced 
apoptosis and downregulated p-STAT3, Bcl-2, and survivin in cutaneous T-cell lymphoma cells. 
Avicin D did not change STAT3 expression, but it decreased phospho-STAT3 protein levels [13,187].  
Betulinic acid inhibited the constitutive activation of STAT3, Src kinase, JAK1, and JAK2. 
Pervanadate reversed the betulinic acid induced down regulation of STAT3 activation, suggesting the 
involvement of a protein tyrosine phosphatase (PTP). Betulinic acid also downregulated the expression 
of STAT3 regulated gene products, such as Bcl-xL, Bcl-2, cyclin D1, and survivin. This correlated 
with an increase in apoptosis as indicated by an increase in the sub-G1 cell population and an increase 
in caspase-3-induced PARP cleavage [188].  
Recently, some researchers found that natural triterpenic diols promote apoptosis in astrocytoma 
cells through ROS-mediated mitochondrial depolarization and JNK activation. Alcohols extracted 
from olive oil, erythrodiol (an intermediate from oleanolic acid), and its isomer, uvaol, have been 
reported anticancerous, particularly on brain cancer cells. Erythrodiol and uvaol effectively affected 
cell proliferation as well as cell cycle phases and induced 1321N1 cell death and modulated the 
apoptotic response, promoting nuclear condensation and fragmentation. These results may be due to 
production of ROS with loss of mitochondrial transmembrane potential, and correlated with the 
activation of JNK. The presence of catalase reversed the triterpenic diols induced mitochondrial 
depolarization, JNK activation, and apoptotic death, indicating the critical role of ROS in the action of 
diols ring compounds [189]. Oleanolic acid also upregulated COX-2 expression and induced 
prostacyclin (PGI2) synthesis. These effects may be as a result of the early activation of cAMP 
regulatory element-binding protein (CREB), a key transcription factor involved in COX-2 
transcriptional upregulation. Oleanolic acid has also shown cardioprotective effects [190]. 
Maslinic acid is present in high concentrations in olive pomace. Various studies have examined the 
responses of HT-29 and Caco-2 colon cancer cell lines to maslinic acid treatment. It also induced 
strong G0/G1 cell-cycle arrest and DNA fragmentation, and increased caspase-3 activity. However, 
maslinic acid did not alter the cell cycle or induce apoptosis in the non-tumorous intestinal cell lines 
IEC-6 and IEC-18 [191].  
Momordin inhibited proliferation and induced apoptosis in human promyelocytic leukemia (HL-60) 
cells and was cytotoxic to HL-60 cells with an IC50 of 19.0 μg/mL. The antiproliferative effects of 
momordin appear to be attributable to its induction of apoptotic cell death, as momordin induced 
nuclear morphology changes and internucleosomal DNA fragmentation and increased the proportion 
of hypodiploid cells. Momordin decreased the expression of the antiapoptotic protein Bcl-2 but Toxins 2010, 2 
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increased the expression of the proapoptotic protein Bax. In addition, treatment with momordin 
induced the activation of caspase-3 and the cleavage of PARP [105]. Many of the triterpenoids derived 
from nature, target caspases, which are essential for apoptotic cell death. 
Saikosaponins were found to be cytotoxic in different cancer cell lines and to exert significant 
inhibition of nitric oxide production in LPS-induced RAW 264.7 macrophages, with IC50  
of 4.2 and 10.4 μM, respectively [170]. Saikosaponins have shown a variety of pharmacological and 
immunomodulatory activities, including anti-inflammatory, antibacterial, antiviral and anticancer 
effects. Treatment of MDA-MB-231 with saikosaponin-A increased the population of cells in the 
sub-G1 phases of the cell cycle. These results showed that apoptosis in MDA-MB-231 cells was 
independent of the p53/p21 pathway mechanism and was accompanied by an increased ratio of Bax to 
Bcl-2, increased c-myc levels, and increased activation of caspase-3. In contrast, apoptosis of MCF7 
cells may have been initiated by the Bcl-2 family of proteins and involved the p53/p21-dependent 
pathway mechanism, and it was accompanied by an increased level of c-myc protein [192]. In another 
study, an enhancement in Fas and its two ligands, membrane-bound Fas ligand (mFasL) and soluble 
Fas ligand (sFasL), as well as Bax protein, was shown to be responsible for the apoptotic effect 
induced by saikosaponins [121]. Saikosaponins significantly increased the levels of c-myc and p53 
mRNA  [193]. Saikosaponins also caused G0/G1 cell cycle arrest of activated T cells by 
downregulating the protein levels of CDK6 and cyclin D3 and upregulating the protein level of 
p27(kip) [194]. 
The inhibition of NF-κB activation by ursolic acid correlated with the suppression of NF-κB 
dependent cyclin D1, COX-2, and MMP9 expression [125].  Ursolic  acid blocked cell cycle 
progression in the G1 phase and was associated with a marked decrease in the protein expression of 
cyclin D1, D2, and E, and their activating partners cdk2, cdk4, and cdk6 with concomitant induction of 
p21. The accumulation of p21/WAF1 might be p53 dependent. The accumulation of p21/WAF1 
correlated with the upregulation of Fas, the Fas ligands and Bax, and the downregulation of NF-κB, 
Bcl-2, and Bcl-xL [121]. Ursolic acid also upregulated apoptotic genes p53 and caspase-3, while the 
antiapoptotic gene Bcl-2 was downregulated [124].  
CDDO, concentrated at 1–5 μM, induced apoptosis in various cancer cell lines. Moreover, CDDO 
combined with TRAIL promoted the induction of apoptosis. CDDO normally acts through both the 
extrinsic and intrinsic pathways by activating the cleavage of BID and of caspases-3, -8, and -9; by 
downregulating FLIP; or by inducing the translocation of Bax to the mitochondria and the release of 
cytochrome C [195−197]. The antitumor activity of CDDO-Me was associated with the inhibition of 
p-Akt, mammalian target of rapamycin (mTOR), and NF-κB signaling proteins and their downstream 
targets such as p-Bad and p-Foxo3a for Akt; p-S6K1, p-eIF-4E and p-4E-BP1 for mTOR; and COX-2, 
VEGF and cyclin D1 for NF-κB [167]. 
Acetyl-11-keto-β-boswellic acid (AKBA), a derivative of boswellic acid has been shown to induce 
apoptosis in cancer cells. AKBA mediated inhibition of the phosphatidylinositol-3-kinase (PI3K)/Akt 
pathway; this pathway is crucial for cell proliferation and survival [198]. Another study showed that 
cyclin D1 and E, CDK2 and 4 and phosphorylated retinoblastoma protein (Rb) were decreased in 
AKBA-treated cells, while p21expression was increased. The growth inhibitory effect of AKBA was 
dependent on p21 but not p53 [199]. The cytostatic and apoptosis inducing activities of boswellic acids 
toward malignant cell lines has been shown in vitro [200]. Boswellic acids triggered apoptosis by Toxins 2010, 2 
 
2446
means of a pathway dependent on caspase-8 activation but independent of Fas/Fas ligand interaction in 
colon cancer cells [201]. AKBA inhibited the NF-κB-dependent reporter gene expression activated by 
TNFR, TRADD, TRAF2, NIK, and IKK, but not that activated by the p65 subunit of NF-κB, which 
indicates that AKBA enhances apoptosis induced by cytokines and chemotherapeutic agents [46]. 
In HT-29 human colon cancer cells, platycodon induced apoptosis through DNA fragmentation and 
PARP cleavage. The apoptosis induced by platycodon was associated with the activation of initiator 
caspases-8 and -9 as well as effector caspase-3. Platycodon stimulated Bid cleavage, indicating that the 
apoptotic action of caspase-8-mediated Bid cleavage leads to the activation of caspase-9. It increased 
the expression of the proapoptotic protein Bax and decreased the expression of the antiapoptotic 
protein Bcl-2. Platycodon also increased the expression of the caspase-independent mitochondrial 
apoptosis factor, apoptosis inducing factor (AIF), in HT-29 cells. Thus, platycodon exerts its apoptotic 
effect via both caspase-dependent and caspase-independent pathways [116,202,203]. 
A few triterpenoid compounds have been shown to both activate caspase activity and downregulate 
the expression of Bcl-2 or Bcl-xL. The ability to suppress proliferation and induce apoptosis in human 
cancer cells is clearly important for drugs targeting either malignant cells in treatment or premalignant 
cells in prevention. 
One of the hallmarks of cancer is aggressive proliferation of cells. In a normal cell, a fine balance 
between growth signals and antigrowth signals regulates proliferation. However, this fine orchestration 
is lost in cancer cells, which often show uncontrolled growth due to the loss of both growth-controlling 
factors. On one hand, cancer cells acquire the capability to generate their own growth signals, while on 
the other hand, they also become unresponsive to antigrowth signals [204]. Numerous factors regulate 
the natural progression of a normal cell. Some of these factors, such as cyclins, are upregulated in 
cancer cells, causing the cells to replicate uncontrollably. Cyclins are the regulatory proteins that 
control the cell cycle, while other factors such as COX-2 and c-myc play a supporting role. The most 
commonly affected cyclin in cancer cells is cyclin D1, an important cell cycle regulator that plays a 
role in transition of the cell from the G1 phase to the S phase. Cancer cells show overexpression of this 
cyclin D1 and thus it has been linked to the development and progression of cancer. 
Avicins downregulate both STAT3 and the expression of STAT3-regulated prosurvival proteins, 
which contribute to the induction of apoptosis in tumor cells. STAT3 plays an important role in 
inflammation and wounding, and the in vivo inhibition of VEGF. In a mouse skin carcinogenesis 
model, avicins inhibited the expression of STAT3, resulting in the suppression of the   
pro-inflammatory and pro-oxidant stromal environment of tumors  [11]. Avicins at concentrations   
of 0.5–5.0 μg/mL caused more apoptosis in patients' Sézary cells than in healthy donors' CD4+ T cells 
and activated CD4+ T cells and decreased apoptosis inhibitors bcl-2 and survivin [13]. Furthermore, 
avicin D-induced autophagic cell death was abrogated by knockdown of tuberous sclerosis complex 2 
(TSC2), a key mediator linking AMP-activated protein kinase (AMPK) to mTOR inhibition, 
suggesting that AMPK activation is a crucial event targeted by avicins. Avicins also have been shown 
to lower energy of metabolism in tumor cells by targeting the outer mitochondrial membrane, causing 
cancer cell death [187]. Tumor cells generate hydroperoxides at a very high rate, and avicins could 
provide a new strategy of anticancer therapy by sensitizing cells with high levels of ROS to apoptosis. 
In another study, boswellic acids, which inhibit STAT3 activation, led to the suppression of gene 
products involved in proliferation (cyclin D1), survival (Bcl-2, Bcl-xL, and Mcl-1), and angiogenesis 
(VEGF) [32]. Toxins 2010, 2 
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Maslinic acid has shown an antiproliferative effect against Caco-2 cancer cells (EC50 = 15 µM), 
HT-29 human colon cancer cells (EC50 = 74 µM), 1321N1 astrocytoma cells (EC50 = 25 µM), and 
human leukemia cells (CCRF-CEM and CEM/ADR5000) (EC50 = 7 and 9 µM, respectively). Maslinic 
acid’s antiproliferative activity likely comes from the induction of an oxidative apoptotic pathway, 
which causes cell cycle and cytoskeleton alterations. Maslinic acid has been found to attenuate 
intracellular oxidative stress by inhibiting of NO and H2O2 production and reducing proinflammatory 
cytokine generation in murine macrophages [205]. Maslinic acid inhibited cell growth with an EC50  
of 101.2 μM without necrotic effects. This effect of maslinic acid is caused by a hydroxyl group at the 
carbon 2 position, ultimately activates caspase-3 as a prime apoptosis protease  [206]. A 200 μM 
concentration of maslinic acid was sufficient for activating caspase-3, which inhibits cell 
proliferation  [207]. Maslinic acid from pomace olive oil demonstrated a suppressive effect on 
oxidative stress and cytokine production in stimulated murine macrophages [208].  Triterpenoids 
isolated from apple peels have shown potent antiproliferative activity and may be partially responsible 
for apples’ anticancer activity. 
Saikosaponins prevented the proliferation of MCF-7 cell at the concentration of 10 nM to 10 μM 
and was significantly inhibited by the specific estrogen receptor (ER) antagonist ICI-182780 [209]. 
This antiproliferative effect is due to the synthesis of extracellular matrix proteins through the 
downregulation of the CDK4, c-Jun, and c-Fos genes [210], which block cell cycle progression at the 
G1 phase. 
The potency of ursolic acid was associated with ZIP/p62 and protein kinase C-zeta (PKC-zeta). 
Ursolic acid inhibited the interaction of ZIP/p62 and PKC-zeta. It also further suppressed the 
activation of NF-κB and the downregulation of the MMP9 protein, which in turn contributed to ursolic 
acid’s inhibitory effects on IL-1β or TNF-induced C6 glioma cell invasion [127]. Ursolic acid showed 
the strongest inhibitory activity to urokinase (IC50 = 12 μM) and cathepsin B (IC50 = 10 μM), and as 
proteases are involved in tumor invasion and metastasis, this activity could be beneficial in cancer 
treatment [211]. CDDO-Me inhibited growth and induced apoptosis in PC-3 and C4-2 cells and was 
associated with the inhibition of the p-Akt, mTOR, and NF-κB signaling proteins and COX-2, VEGF 
and cyclin D1  [167]. Some of the triterpenoid derivatives obtained from ursolic acid have shown 
ability to suppress the de novo formation of two enzymes, iNOS and COX-2, in IFN-γ-stimulated 
primary mouse macrophages or LPS-activated RAW 264.7 macrophages that are used as assay 
systems [212].  
The inhibition of STAT3 activation by boswellic acids led to the suppression of gene products 
involved in proliferation (cyclin D1), survival (Bcl-2, Bcl-xL, and Mcl-1), and angiogenesis (VEGF. 
Betulinic acid combined with vincristine showed a synergistic cytotoxic effect on melanoma cells, 
inducing cell cycle arrest at different points (betulinic acid at G1 phase and vincristine at G2/M phase) 
and causing apoptosis in B16F10 melanoma cells. In C57BL/6 mice, vincristine inhibited metastasis of 
melanoma cells to the lung, an effect that was augmented by the addition of betulinic acid [213]. 
4.3. Role of Triterpenoids in Invasion, Metastasis, and Angiogenesis 
Besides uncontrolled proliferation, the other major characteristics of cancer cells are invasion and 
metastasis. In metastasis the cancer cells migrate from their original site of origin to other parts of the 
body, either via the bloodstream or lymphatic system. Among the factors influencing invasion, which Toxins 2010, 2 
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affects whether or not a tumor will metastasize, are MMPs and ICAM-1. MMPs (specifically MMP2 
and MMP9) are endopeptidases that degrade the basement membrane components, separating the cells 
from their surrounding tissue and enabling them to move freely and spread to other tissues [214]. 
Chemokine receptor CCR7 is important for lymphatic invasion of cancer cells and is overexpressed in 
metastatic breast cancer cells; withanolide inhibits TAK1 to repress NF-κB-induced CCR7 expression 
in breast cancer cells and is useful for the prevention of lymphatic involvement by breast cancer 
cells [215]. 
Erythrodiol-3-acetate, a triterpenoid, reduced the level of MMP1 and induced type 1 procollagen in 
a dose dependent manner [216]. Ganoderma lucidum, a well known mushroom containing platycodon, 
showed a significant inhibitory effect on PMA-induced MMP9 and MMP2 activation in a dose 
dependent manner and further inhibited HT-1080 and HepG2 cell invasion and migration  [217]. 
Another study found that boswellic acids potentiated the apoptosis induced by TNF and 
chemotherapeutic agents, suppressed TNF-induced invasion, and inhibited NF-κB-induced 
osteoclastogenesis [46]. 
Angiogenesis is the basis for solid tumor development and distribution, and antiangiogenic drugs 
have been demonstrated to be active at the site of cancer. The growth of human tumors and 
development of metastases depends on the de novo formation of blood vessels [218]. Angiogenesis, 
the physiological process in which new blood vessels develop from pre-existing ones, normally occurs 
during growth, reproduction, and wound healing; however, this process is also a marker indicating that 
a tumor has progressed from a dormant to malignant state. Angiogenesis favors tumor growth by 
providing oxygen and nutrients to multiplying cells via the newly formed blood vessels. Some 
proangiogenic factors that favor development of new blood vessels include IL-8, TNF, fibroblast 
growth factor-2 (FGF-2), and PDGF. However, the most important factor in the whole process of 
angiogenesis is VEGF. Various studies have shown it to be a potent stimulator of angiogenesis 
in vitro [218]. Because of its critical role in angiogenesis, it has been targeted for controlling tumor 
progression. Limiting VEGF in tumors has been shown to lead to blood vessel destruction and to 
prevent the growth of new ones, thus reducing the blood supply to the tumor. Inhibition of the VEGF 
tyrosine kinase signaling pathway blocked angiogenesis in growing tumors, leading to stasis and 
regression of the tumors. Thus, agents that can downregulate or inhibit the expression of VEGF or its 
signaling pathway in tumor cells could prove to be very promising in preventing tumor growth   
and metastasis. 
Saikosaponin C, one of the saikosaponins present in a Chinese herb, Radix bupleuri, has been found 
to have a potent inducing effect on human umbilical vein endothelial cells’ viability and growth. 
Saikosaponin C also induced endothelial cell migration and capillary tube formation. Saikosaponin C 
induced the gene expression or activation of MMP2, VEGF, and the p42/p44 MAPK that correlates 
with endothelial cell growth, migration, and angiogenesis, respectively [219]. Another study found that 
saikosaponins can inhibit the physiological angiogenesis of chicken embryos, especially for the 
medium and small vessels [220]. 
CDDO-Me and CDDO-Im were shown to inhibit the activation of the ERK1/2 pathway after 
stimulation with VEGF in human umbilical vein endothelial cells [221]. CDDO-Me also potentiated 
the cytotoxic effects of TNF and chemotherapeutic agents. This may be because CDDO-Me inhibits 
NF-κB through the inhibition of IκBα kinase, leading to the suppression of NF-κB-regulated gene 
product (VEGF, COX-2, and MMP9) expression and to angiogenesis  [222]. Boswellic acids Toxins 2010, 2 
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suppressed VEGF-induced phosphorylation of VEGF receptor 2 (VEGFR2) kinase (KDR/Flk-1) with 
an IC50 of 1.68 μM. Specifically, boswellic acids suppressed the downstream protein kinases of 
VEGFR2, including Src family kinase, focal adhesion kinase, ERK, AKT, mTOR, and ribosomal 
protein S6 kinase  [223]. In an ex vivo model, boswellic acids significantly inhibited blood vessel 
formation in the Matrigel plug assay in mice and effectively suppressed VEGF induced microvessel 
sprouting in a rat aortic ring assay. Furthermore, boswellic acids inhibited VEGF induced cell 
proliferation, chemotactic motility, and the formation of capillary-like structures from primary cultured 
human umbilical vascular endothelial cells in a dose-dependent manner [223]. Betulinic acid also 
inhibits growth factor-induced in vitro angiogenesis by modulating mitochondrial function in 
endothelial cells [224]. 
Various  in vivo studies have found that celastrol can downregulate the density of tumor 
microvessels significantly at different doses. Immunohistochemistry showed that celastrol also 
decreased the levels of VEGFR1 and VEGFR2 expression, but not the level of VEGF 
expression [225]. However, avicins, downregulate the expression of VEGF [166]. An in vivo study 
showed that Ganoderma lucidum given at 100 and 200 mg/kg inhibited primary solid tumor growth in 
the spleen, liver metastasis, and secondary metastatic tumor growth in the liver in intrasplenic Lewis 
lung carcinoma-implanted mice. An in vivo assay system extract inhibited Matrigel induced 
angiogenesis [226].  
5. Role of Triterpenoids in Cancer Treatment 
Triterpenoids are structurally diverse organic compounds. More than 20,000 triterpenoid varieties 
are formed by multiple modifications of the basic backbone structure. Several triterpenoids such as 
avicin, betulinic acid, boswellic acids, celastrol, diosgenin, madecassic acid, maslinic acid, momordin, 
saikosaponins, platycodon, pristimerin, ursolic acid, CDDO, and withanolide, have been shown in our 
laboratory and others to possess anticancer and anti-inflammatory activities. Preliminary data from 
ongoing studies indicate that some synthetic triterpenoids are being developed with improved 
anticancer activity. Several triterpenoids are now in clinical trials at different phases (Table 4; 
www.clinicaltrials.gov). Synthetic triterpenoid, CDDO, is being tested in patients with various cancers. 
Betulinic acid ointment is under evaluation for the treatment of dysplastic nevi that have the potential 
to transform into melanoma. Triterpenoids are highly multifunctional and thus have promise as agents 
in the treatment of cancer because of their ability to block the NF-κB activation, induce apoptosis, and 
inhibit proliferation, invasion, metastasis and angiogenesis. 
Table 4. List of triterpenoids in clinical trials. 
Triterpenoids    Cancer  Phase  Status  Sponsors 
CDDO-Me  Solid tumors or   I  Terminated   MDACC 
  Lymphoid malignancies        
CDDO Solid  Tumors  I  Completed  NCI 
 or  Lymphoma       
CDDO-Me Liver  disease  I/II  Terminated  RPI 
Ginsenoside Breast  cancer  II  Ongoing  SIU 
Ginsenoside Hypertension  II  Completed  SMH 
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Table 4. Cont. 
Ginsenoside   Ischemic Stroke  II/III  Completed  XH 
Betulinic acid   Dysplastic nervus syndrome  I/II  Ongoing  UI 
Escin Arm  lymphedema  II  Completed  UW 
Glycyrrhizin Hepatitis  C  III  Ongoing  SP 
Glycyrrhetinic acid   End stage renal disease  II  Ongoing  UHI 
Glycyrrhetinic acid   AME  II/III  Completed  BWH 
MDACC, MD Anderson Cancer Center, U.S.; NCI, National Cancer Institute, U.S.; RPI, Reata 
Pharmaceuticals, Inc; SIU, Southern Illinois University; SMH, St. Michael's Hospital, Toronto; XH, Xijing 
Hospital, China; UI, University of Illinois; UW, University of Wisconsin, U.S.; SP, Schering-Plough; UHI, 
University Hospital Inselspital, Switzerland; AME, Apparent Mineralocorticoid Excess; BWH, Brigham and 
Women's Hospital, U.S. 
6. Conclusions 
This review has illustrated that triterpenoids are important active constituents obtained from various 
plants and could be considered for use in both the chemoprevention and chemotherapy of cancer. 
Inflammatory proteins and their pathways are critical targets in both the prevention and treatment of 
cancer. Therefore, identification of agents or drugs that can suppress these pathways is of enormous 
importance.  
Polycyclic triterpenoids now offer important new platforms for drug development. The natural 
triterpenoid platform provided by the unique stereochemistry of these particular compounds, and the 
cyclization of the linear 30-carbon squalene molecule, have provided an excellent base from which 
new agents more potent than the parent squalene could be developed.  
Thus, agents that can suppress NF-κB and activate caspase and other pathways (e.g., DR4, DR5) 
are likely to be effective drugs. Because of their safety and ability to affect multiple targets, natural 
products are likely to have a special place in the preventive and therapeutic armamentarium against 
cancer. Although there are extensive preclinical data to support such claims, only clinical studies can 
fully validate them.  
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